Luitpold Pharmaceuticals Chooses BioClinica Express EDC

– Vendor Flexibility and Technology Suite Cited as Key to Selection –

August 1, 2012

August 1, 2012.  NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that Luitpold Pharmaceuticals, a pioneer in the development and marketing of a wide variety of drugs and medical devices, will use BioClinica's Express Electronic Data Capture ("EDC") system for multiple upcoming clinical trials.

Luitpold selected BioClinica's Express EDC after a comprehensive search and vendor evaluation process, citing the company's flexibility during the bidding process and advanced technology as important factors in the decision.

"The transparency of BioClinica's solutions and accessibility of the project management team will make BioClinica a true partner in the clinical trial process," said Marc L. Tokars, Vice President of Clinical Operations for Luitpold. "We're excited by the possibilities that BioClinica's advanced technology will bring to Luitpold's future clinical trials."

BioClinica's Express EDC makes every part of the clinical trial process more efficient and easier to manage. Express is a comprehensive EDC solution that uses time-tested, stable technology to provide a central hub to coordinate and organize the collection and dissemination of clean data, adding speed and quality to every part of the clinical trial process.

"We are pleased Luitpold has selected BioClinica's Express EDC for their upcoming trials," said Peter Benton, President of BioClinica's eClinical division. "Luitpold has a proud tradition of pharmaceutical innovation, and we are extremely pleased that BioClinica's comprehensive suite of eClinical solutions will help them continue to bring new drugs to market."

About Luitpold Pharmaceuticals, Inc.
Luitpold Pharmaceuticals, Inc., a Daiichi Sankyo Group Company, headquartered in Shirley, NY, manufactures over 80 pharmaceutical products including Venofer® (iron sucrose injection, USP), the # 1 selling IV iron therapy in the U.S., which are distributed through its human health subsidiary, American Regent, Inc. Luitpold Pharmaceuticals, also markets dental bone regeneration products and veterinary pharmaceuticals through its Osteohealth and Animal Health divisions respectively. Sprix® (ketorolac tromethamine) Nasal Spray is marketed through its Regency Therapeutics Division. For more information on Luitpold or any of its divisions and products, please visit: www.luitpold.com.

About Bioclinica

Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized by three business segments to deliver focused service supporting multifaceted technologies. The Medical Imaging and Biomarkers segment provides medical imaging and cardiac safety services and includes a molecular marker laboratory. The eHealth Solutions segment comprises an eClinical technology platform and professional services along with safety and regulatory solutions. Under the Global Clinical Research segment, Bioclinica offers a network of research sites, patient recruitment-retention services, and a post-approval research division. The Company serves more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia.
Learn more at www.bioclinica.com.